A Phase 2/3 Study of S-524101 in the Patients with Perennial Allergic Rhinitis
Latest Information Update: 26 Oct 2017
At a glance
- Drugs S 524101 (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Shionogi
- 30 Mar 2015 Based on data from this study, Shionogi has received the approval of S-524101 [STG320] from the Japanese health authorities (PMDA - Pharmaceuticals and Medical Devices Agency), according to a Stallergenes SA media release; it is the first immunotherapy tablet registered in Japan for the treatment of house dust mite-induced allergic rhinitis.
- 13 Feb 2014 New trial record
- 03 Feb 2014 Status changed from active, no longer recruiting to completed, according to a Stallergenes SA media release.